Kura Oncology (KURA) Other Non-Current Liabilities (2014 - 2026)
Kura Oncology (KURA) posted quarterly Other Non-Current Liabilities of $3.4 million for Q1 2026, up 60.68% year-over-year from $2.1 million in Q1 2025, and up 8.59% quarter-over-quarter from $3.2 million in Q4 2025.
Kura Oncology (KURA) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Other Non-Current Liabilities for 13 consecutive years, with $3.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 60.68% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $3.4 million (up 60.68% YoY), while the FY2025 annual figure was $3.2 million, up 76.32% from the prior year.
- Other Non-Current Liabilities climbed to $3.4 million in Q1 2026 per KURA's latest filing, from $3.2 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $3.4 million in Q1 2026 and bottomed at $265000.0 in Q4 2022.
- Historically, Other Non-Current Liabilities has averaged $1.4 million across 5 years, with a median of $951000.0 in 2024.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities decreased 29.33% — and 2024, when it jumped 170.94%.
- Kura Oncology's Other Non-Current Liabilities stood at $265000.0 in 2022, then jumped by 166.04% to $705000.0 in 2023, then jumped by 154.61% to $1.8 million in 2024, then surged by 76.32% to $3.2 million in 2025, then grew by 8.59% to $3.4 million in 2026.
- Business Quant data shows KURA's Other Non-Current Liabilities at $3.4 million in Q1 2026, $3.2 million in Q4 2025, and $3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.62 Mn |
| Mar 31, 2026 | 3.44 Mn |
| Dec 31, 2025 | 3.17 Mn |
| Sep 30, 2025 | 2.98 Mn |
| Jun 30, 2025 | 2.60 Mn |
| Mar 31, 2025 | 2.14 Mn |
| Dec 31, 2024 | 1.80 Mn |
| Sep 30, 2024 | 1.47 Mn |
| Jun 30, 2024 | 1.18 Mn |
| Mar 31, 2024 | 951,000.00 |
| Dec 31, 2023 | 705,000.00 |
| Sep 30, 2023 | 567,000.00 |
| Jun 30, 2023 | 461,000.00 |
| Mar 31, 2023 | 351,000.00 |
| Dec 31, 2022 | 265,000.00 |
| Sep 30, 2022 | 542,000.00 |
| Jun 30, 2022 | 459,000.00 |
| Mar 31, 2022 | 496,000.00 |
| Dec 31, 2021 | 375,000.00 |
| Sep 30, 2021 | 356,000.00 |